[go: up one dir, main page]

PE20191150A1 - Receptores de celulas t con apareamiento mejorado - Google Patents

Receptores de celulas t con apareamiento mejorado

Info

Publication number
PE20191150A1
PE20191150A1 PE2019001163A PE2019001163A PE20191150A1 PE 20191150 A1 PE20191150 A1 PE 20191150A1 PE 2019001163 A PE2019001163 A PE 2019001163A PE 2019001163 A PE2019001163 A PE 2019001163A PE 20191150 A1 PE20191150 A1 PE 20191150A1
Authority
PE
Peru
Prior art keywords
cell receptors
pairing
amino acid
enhanced
modified alpha
Prior art date
Application number
PE2019001163A
Other languages
English (en)
Inventor
Jens Fritsche
Claudia Wagner
Dominik Maurer
Leonie Alten
Sebastian Bunk
Franziska Hoffgaard
Mathias Ferber
Original Assignee
Immatics Biotechnologies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immatics Biotechnologies Gmbh filed Critical Immatics Biotechnologies Gmbh
Publication of PE20191150A1 publication Critical patent/PE20191150A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)

Abstract

La presente invencion se relaciona con cadenas alfa o beta modificadas de receptor de celula T (TCR), o heterodimeros que comprenden las mismas, en donde en el dominio variable de dicha cadena alfa o beta modificada, se sustituye un aminoacido en la posicion 44 de acuerdo con la numeracion de IMGT por otro aminoacido adecuado con el objetivo de mejorar el apareamiento de cadenas deseadas.
PE2019001163A 2016-12-08 2017-12-06 Receptores de celulas t con apareamiento mejorado PE20191150A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662497895P 2016-12-08 2016-12-08
DE102016123893.7A DE102016123893A1 (de) 2016-12-08 2016-12-08 T-Zellrezeptoren mit verbesserter Bindung

Publications (1)

Publication Number Publication Date
PE20191150A1 true PE20191150A1 (es) 2019-09-02

Family

ID=62201182

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2019001163A PE20191150A1 (es) 2016-12-08 2017-12-06 Receptores de celulas t con apareamiento mejorado

Country Status (14)

Country Link
US (2) US11072645B2 (es)
EP (1) EP3551653B1 (es)
JP (1) JP7346294B2 (es)
CN (1) CN110099923A (es)
AU (1) AU2017371260C1 (es)
BR (1) BR112019010803A2 (es)
CA (1) CA3045230A1 (es)
CR (1) CR20190280A (es)
DE (1) DE102016123893A1 (es)
MA (1) MA47359A (es)
MX (1) MX2019006726A (es)
PE (1) PE20191150A1 (es)
TW (1) TWI710572B (es)
WO (1) WO2018104407A1 (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201319446D0 (en) 2013-11-04 2013-12-18 Immatics Biotechnologies Gmbh Personalized immunotherapy against several neuronal and brain tumors
WO2021173560A1 (en) 2020-02-24 2021-09-02 Immatics US, Inc. Methods for expanding t cells for the treatment of cancer and related malignancies
GB201604458D0 (en) 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against cancers
KR20240007775A (ko) 2016-12-08 2024-01-16 이매틱스 바이오테크놀로지스 게엠베하 T 세포 수용체 및 이를 사용하는 면역 요법
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
DE102017106305A1 (de) 2017-03-23 2018-09-27 Immatics Biotechnologies Gmbh Neue T-Zellrezeptoren und deren Verwendung in Immuntherapien gegen prame-positive Krebsarten
DE102017125888A1 (de) 2017-11-06 2019-05-23 Immatics Biotechnologies Gmbh Neue konstruierte T-Zell-Rezeptoren und deren Verwendung in Immuntherapie
EP4219543A1 (en) 2017-11-06 2023-08-02 Immatics Biotechnologies GmbH Novel engineered t cell receptors and immune therapy using the same
DE102018108612A1 (de) 2018-03-21 2019-09-26 Immatics US, Inc. Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen
WO2020191172A1 (en) 2019-03-19 2020-09-24 Immatics US, Inc. Cd28 t cell cultures, compositions, and methods of using thereof
DE102019108125B4 (de) 2019-03-28 2022-02-03 Immatics US, Inc. Cd28 t-zellkulturen, zusammensetzungen und verfahren zu deren verwendung
TWI872076B (zh) 2019-05-27 2025-02-11 美商英麥提克斯股份有限公司 病毒載體及其在授受性細胞療法之應用
DE102019121007A1 (de) 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Antigenbindende Proteine, die spezifisch an MAGE-A binden
JP2023525423A (ja) 2020-01-15 2023-06-16 イマティクス バイオテクノロジーズ ゲーエムベーハー Ｐｒａｍｅに特異的に結合する抗原結合タンパク質
DE102020111571A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
TW202227616A (zh) 2020-08-21 2022-07-16 美商英麥提克斯股份有限公司 分離ｃｄ８＋選擇ｔ細胞的方法
MX2023007817A (es) 2020-12-31 2023-09-13 Immatics Us Inc Polipéptidos de cd8, composiciones y métodos de uso de estos.
WO2022184805A1 (en) 2021-03-03 2022-09-09 Immatics Biotechnologies Gmbh Antigen binding proteins specifically binding sars-cov-2 antigenic peptides in complex with a major histocompatibility complex protein
IL308257A (en) 2021-05-05 2024-01-01 Immatics Biotechnologies Gmbh Antigen binding proteins that uniquely bind PRAME
TW202321277A (zh) 2021-07-27 2023-06-01 德商英麥提克生物技術股份有限公司 特異性結合ｃｔ４５之抗原結合蛋白
US20230089392A1 (en) 2021-09-20 2023-03-23 Immatics US, Inc. Monocyte depletion of t cells populations for t-cell therapy
WO2023081461A1 (en) 2021-11-08 2023-05-11 Immatics US, Inc. Methods for generating cell spheroids
EP4448108A1 (en) 2021-11-08 2024-10-23 Immatics Biotechnologies GmbH Adoptive cell therapy combination treatment and compositions thereof
EP4198052A1 (en) 2021-12-15 2023-06-21 Eberhard Karls Universität Tübingen Medizinische Fakultät Peptides and antigen binding proteins for use in immunotherapy against fibrolamellar hepatocellular carcinoma (fl-hcc) and other cancers
JP2025515604A (ja) 2022-04-28 2025-05-20 イマティクス ユーエス，アイエヌシー． ドミナントネガティブＴＧＦβ受容体ポリペプチド、ＣＤ８ポリペプチド、細胞、組成物、およびその使用方法
CA3250304A1 (en) 2022-04-28 2023-11-02 Immatics US, Inc. IL-15 Bound to a Membrane, CD8 Polypeptides, Cells, Compositions and Related Methods of Use
WO2023212655A1 (en) 2022-04-28 2023-11-02 Immatics US, Inc. Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof
EP4519418A1 (en) 2022-05-05 2025-03-12 Immatics US, Inc. Methods for improving t cell efficacy
WO2025021979A1 (en) 2023-07-27 2025-01-30 Immatics Biotechnologies Gmbh Novel t cell receptors targeting melanoma-associated antigen (mage) b2 and immune therapy using the same
TW202506719A (zh) 2023-07-27 2025-02-16 德商艾瑪提克生物技術有限公司 針對mageb2之抗原結合蛋白
WO2025096649A1 (en) 2023-11-01 2025-05-08 Immatics US, Inc. Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof
WO2026008886A1 (en) 2024-07-05 2026-01-08 Immatics Biotechnologies Gmbh Means and methods for the quantification of target expression
WO2026025031A1 (en) 2024-07-26 2026-01-29 Modernatx, Inc. Mrna encoding mageb2 tcer molecule

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2244744A1 (en) * 1996-02-01 1997-08-07 University Of Florida Lyst1 and lyst2 gene compositions and methods of use
WO2000052163A1 (en) 1999-03-02 2000-09-08 Ludwig Institute For Cancer Research Cloning of cdna of mage's 5, 8, 9 and 11 and their uses in diagnosis of cancer
CA2393730A1 (en) 1999-12-13 2001-06-14 Epimmune Inc. Hla class i a2 tumor associated antigen peptides and vaccine compositions
JP4900884B2 (ja) 2000-07-31 2012-03-21 株式会社グリーンペプタイド 腫瘍抗原
CA2481304A1 (en) 2002-03-27 2003-10-09 Patrick Hwu Method for treating cancer in humans
DE10225144A1 (de) 2002-05-29 2003-12-18 Immatics Biotechnologies Gmbh An MHC-Moleküle bindende Tumor-assoziierte Peptide
DE10225139A1 (de) 2002-05-29 2004-02-26 Immatics Biotechnologies Gmbh Verfahren zur Identifizierung von immunreaktiven Peptiden
DE10313819A1 (de) 2003-03-24 2004-10-07 Immatics Biotechnologies Gmbh An MHC-Moleküle bindende Tumor-assoziierte Peptide
US7807392B1 (en) 2003-09-15 2010-10-05 Celera Corporation Lung disease targets and uses thereof
US7811828B2 (en) 2004-01-28 2010-10-12 Immatics Biotechnologies Gmbh Method for identifying and quantifying of tumuor-associated
DE102004026135A1 (de) 2004-05-25 2006-01-05 Immatics Biotechnologies Gmbh An MHC-Moleküle bindende Tumor-assoziierte Peptide
MX2007010349A (es) 2005-02-24 2008-04-09 Cemines Inc Composiciones y metodos para clasificar muestras biologicas.
ATE512160T1 (de) 2005-04-26 2011-06-15 Immatics Biotechnologies Gmbh T-cell-epitope aus dem unreifen lamininrezeptorprotein (oncofoetal antigen) und deren medizinische verwendungen
SI1760089T1 (sl) 2005-09-05 2009-12-31 Immatics Biotechnologies Gmbh S tumorjem povezani peptidi, ki se veĹľejo na molekule humanega levkocitnega antigena (HLA) razreda I ali II in ustrezno cepivo proti raku
EP1806359B1 (en) 2005-09-05 2010-03-17 Immatics Biotechnologies GmbH Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules
WO2008053573A1 (fr) 2006-10-30 2008-05-08 National University Corporation Hokkaido University Remède pour néoplasme malin
EA018456B1 (ru) 2007-07-27 2013-08-30 Имматикс Байотекнолоджиз Гмбх Новые иммуногенные эпитопы для иммунотерапии
MX2010001086A (es) 2007-07-27 2010-04-09 Immatics Biotechnologies Gmbh Nueva inmunoterapia contra tumores neuronales y cerebrales.
UA103882C2 (uk) 2007-07-27 2013-12-10 Імматікс Біотекнолоджіс Гмбх Композиція пухлино-асоційованих пептидів та відповідна протиракова вакцина
US8603810B2 (en) * 2008-05-09 2013-12-10 Agency For Science, Technology And Research T-cell having a T-cell receptor that recognizes epitope HBC18-27 of hepatitis B viral core antigen
SI2119726T2 (en) 2008-05-14 2018-03-30 Immatics Biotechnologies Gmbh New and powerful Class II MHC peptides derived from survivin and neurocane
TW201008574A (en) 2008-08-19 2010-03-01 Oncotherapy Science Inc INHBB epitope peptides and vaccines containing the same
PT2172211E (pt) 2008-10-01 2015-03-09 Immatics Biotechnologies Gmbh Composição de peptídeos associados a tumores e vacina anti -cancro relacionada para o tratamento de glioblastoma (gbm) e outros tipos de câncer
WO2010037395A2 (en) 2008-10-01 2010-04-08 Dako Denmark A/S Mhc multimers in cancer vaccines and immune monitoring
GB0917094D0 (en) * 2009-09-29 2009-11-11 Ucl Biomedica Plc T-cell receptor
WO2011066265A1 (en) 2009-11-25 2011-06-03 Ludwig Institute For Cancer Research Ltd. Cancer testis antigens as biomarkers in non-small cell lung cancer
US9023802B2 (en) 2009-12-14 2015-05-05 Immatics Biotechnologies Gmbh HLA-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
GB201004575D0 (en) 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers
GB201019331D0 (en) 2010-03-19 2010-12-29 Immatics Biotechnologies Gmbh Methods for the diagnosis and treatment of cancer based on AVL9
GB201004551D0 (en) 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
GB201006360D0 (en) 2010-04-16 2010-06-02 Immatics Biotechnologies Gmbh Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development
US9114100B2 (en) 2010-05-17 2015-08-25 Duke University Methods of treatment using ex vivo expansion of cord blood T cells
GB201009222D0 (en) 2010-06-02 2010-07-21 Immatics Biotechnologies Gmbh Improved cancer therapy based on tumour associated antigens derived from cyclin D1
CN101870725B (zh) 2010-06-29 2012-06-27 郑州大学 Mage-4抗肿瘤ctl表位肽及其应用
GB201015765D0 (en) 2010-09-21 2010-10-27 Immatics Biotechnologies Gmbh Use of myeloid cell biomarkers for the diagnosis of cancer
GB201021289D0 (en) 2010-12-15 2011-01-26 Immatics Biotechnologies Gmbh Novel biomarkers for a prediction of the outcome of an immunotherapy against cancer
AU2011344652B2 (en) 2010-12-14 2015-11-19 Immatics Biotechnologies Gmbh HLA-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
CA2847332A1 (en) 2011-08-31 2013-03-07 Mie University Vaccine preparation for cancer treatment
GB2508414A (en) 2012-11-30 2014-06-04 Max Delbrueck Centrum Tumour specific T cell receptors (TCRs)
JP6346266B2 (ja) 2013-03-21 2018-06-20 サンガモ セラピューティクス， インコーポレイテッド 操作されたジンクフィンガータンパク質ヌクレアーゼを使用するｔ細胞受容体遺伝子の標的化された破壊
TWI777196B (zh) 2013-08-05 2022-09-11 德商伊瑪提克斯生物科技有限公司 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物（五）
PE20150600A1 (es) 2013-10-15 2015-06-03 Vignolo Carlos Alberto Ibanez CICLO - BICICLETA HIBRIDA MOTORIZADA 2 x 2
GB201319446D0 (en) 2013-11-04 2013-12-18 Immatics Biotechnologies Gmbh Personalized immunotherapy against several neuronal and brain tumors
GB201408255D0 (en) 2014-05-09 2014-06-25 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumours of the blood, such as acute myeloid leukemia (AML)
WO2015172843A1 (en) 2014-05-16 2015-11-19 Biontech Diagnostics Gmbh Methods and kits for the diagnosis of cancer
GB201411037D0 (en) 2014-06-20 2014-08-06 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemai (CLL)
GB2528124A (en) 2014-07-11 2016-01-13 Nec Corp Communication system
US10973894B2 (en) 2014-10-02 2021-04-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Methods of isolating T cells having antigenic specificity for a cancer-specific mutation
TWI617841B (zh) 2014-10-22 2018-03-11 英特爾股份有限公司 用於光學系統的防雲紋圖樣擴散器
WO2016064317A1 (en) 2014-10-24 2016-04-28 Telefonaktiebolaget L M Ericsson (Publ) Method and arrangement for csi-rs transmission
CN104460328B (zh) 2014-10-29 2019-05-10 小米科技有限责任公司 基于设定场景模式的智能设备控制方法和装置
KR102492684B1 (ko) 2014-10-30 2023-01-26 에코젠서스, 엘엘씨 혼합 고형 폐기물로부터 형성된 고형 연료 조성물
DE102014016105A1 (de) 2014-10-30 2016-05-04 Head Technology Gmbh Superelastische Schlägersaite
US20190030071A1 (en) 2014-11-03 2019-01-31 IMMURES S.r.I. T cell receptors
MA40904A (fr) 2014-11-03 2017-09-12 Hygeia Tech Inc Compositions d'ester de phorbol et procédés pour traiter ou réduire la durée d'une cytopénie
US10786360B2 (en) 2014-11-04 2020-09-29 Spinal Stabilization Technologies Llc Percutaneous implantable nuclear prosthesis
WO2016079737A2 (en) 2014-11-17 2016-05-26 Mitrassist Medical Ltd. Heart valve prosthesis
KR20170054544A (ko) 2014-11-20 2017-05-17 에이비비 슈바이쯔 아게 전자기 브레이크 시스템 및 금속 제조 프로세스에서 용융 금속 유동을 제어하는 방법
DE102014223758A1 (de) 2014-11-20 2016-05-25 Windmöller & Hölscher Kg Kontaktwalze
GB201501017D0 (en) 2014-12-23 2015-03-04 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
GB201423361D0 (en) 2014-12-30 2015-02-11 Immatics Biotechnologies Gmbh Method for the absolute Quantification of naturally processed HLA-Restricted cancer peptides
EP3067366A1 (en) 2015-03-13 2016-09-14 Max-Delbrück-Centrum Für Molekulare Medizin Combined T cell receptor gene therapy of cancer against MHC I and MHC II-restricted epitopes of the tumor antigen NY-ESO-1
GB201504502D0 (en) 2015-03-17 2015-04-29 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers
GB201505305D0 (en) 2015-03-27 2015-05-13 Immatics Biotechnologies Gmbh Novel Peptides and combination of peptides for use in immunotherapy against various tumors
GB201505585D0 (en) 2015-03-31 2015-05-13 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carinoma (RCC) and other cancers
GB201507030D0 (en) 2015-04-24 2015-06-10 Immatics Biotechnologies Gmbh Immunotherapy against lung cancers, in particular NSCLC
GB201507719D0 (en) 2015-05-06 2015-06-17 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers
GB201510771D0 (en) 2015-06-19 2015-08-05 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy and methods for generating scaffolds for the use against pancreatic cancer
GB201511191D0 (en) 2015-06-25 2015-08-12 Immatics Biotechnologies Gmbh T-cell epitopes for the immunotherapy of myeloma
GB201511546D0 (en) 2015-07-01 2015-08-12 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
GB201511792D0 (en) 2015-07-06 2015-08-19 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against esopageal cancer and other cancers
GB201512369D0 (en) 2015-07-15 2015-08-19 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
GB201513921D0 (en) 2015-08-05 2015-09-23 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
GB201515321D0 (en) 2015-08-28 2015-10-14 Immatics Biotechnologies Gmbh Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers
GB201517538D0 (en) 2015-10-05 2015-11-18 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
JP6862435B2 (ja) 2015-10-09 2021-04-21 イマティクス バイオテクノロジーズ ゲーエムベーハー 抗ｗｔ１／ｈｌａ特異的抗体
CN105219714A (zh) 2015-10-20 2016-01-06 上海隆耀生物科技有限公司 一种用于激活肺癌特异性免疫反应的试剂盒
GB201521746D0 (en) 2015-12-10 2016-01-27 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against CLL and other cancers
GB201521894D0 (en) 2015-12-11 2016-01-27 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against various cancers
GB201522667D0 (en) 2015-12-22 2016-02-03 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
GB201604458D0 (en) 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against cancers
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
DE102016123859B3 (de) 2016-12-08 2018-03-01 Immatics Biotechnologies Gmbh Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie
DE102016123847B3 (de) 2016-12-08 2018-04-05 Immatics Biotechnologies Gmbh Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie
CA3066932A1 (en) 2017-07-04 2019-01-10 Curevac Ag Novel nucleic acid molecules
US20210147550A1 (en) 2017-08-18 2021-05-20 Joshua Michael Francis Antigen-binding proteins targeting shared antigens
CN111315769A (zh) 2017-09-06 2020-06-19 加州理工学院 信号传导和抗原呈递双功能受体(sabr)
CN118256563A (zh) 2017-11-10 2024-06-28 北京卡替医疗技术有限公司 一种扩增免疫细胞的方法
CN120818057A (zh) 2017-12-28 2025-10-21 磨石生物公司 靶向共同抗原的抗原结合蛋白
RS63873B1 (sr) 2018-04-11 2023-02-28 Enterome S A Antigenski peptidi za prevenciju i lečenje raka
EP3796923A4 (en) 2018-05-18 2022-03-09 Children's National Medical Center Improved targeted t-cell therapy
CN112368386A (zh) 2018-05-23 2021-02-12 磨石肿瘤生物技术公司 共有抗原
EP3802614A1 (en) 2018-06-04 2021-04-14 Apo-T B.V. Methods and means for attracting immune effector cells to tumor cells
GB201819540D0 (en) 2018-11-30 2019-01-16 Adaptimmune Ltd T cell modification
BR112021022303A2 (pt) 2019-05-08 2022-01-18 2Seventy Bio Inc Células t manipuladas
CN114585646B (zh) 2019-06-18 2024-09-03 里珍纳龙药品有限公司 Mage-a4 t细胞受体及其使用方法

Also Published As

Publication number Publication date
JP7346294B2 (ja) 2023-09-19
BR112019010803A2 (pt) 2019-10-01
TWI710572B (zh) 2020-11-21
CA3045230A1 (en) 2018-06-14
EP3551653B1 (en) 2023-11-01
EP3551653A1 (en) 2019-10-16
US20180162922A1 (en) 2018-06-14
AU2017371260C1 (en) 2020-11-19
MA47359A (fr) 2019-12-04
DE102016123893A1 (de) 2018-06-14
US11072645B2 (en) 2021-07-27
AU2017371260A1 (en) 2019-06-20
US20210380659A1 (en) 2021-12-09
CN110099923A (zh) 2019-08-06
CR20190280A (es) 2019-10-07
US12297252B2 (en) 2025-05-13
WO2018104407A1 (en) 2018-06-14
TW201827460A (zh) 2018-08-01
AU2017371260B2 (en) 2020-07-23
JP2020500525A (ja) 2020-01-16
MX2019006726A (es) 2019-09-04

Similar Documents

Publication Publication Date Title
PE20191150A1 (es) Receptores de celulas t con apareamiento mejorado
ECSP18066138A (es) Inhibidores de la proteína quinasa 1 que interactua con el receptor
MX2017010673A (es) Heterociclos biciclicos como inhibidores de receptores del factor de crecimiento fibroblastico (fgfr).
CL2016000221A1 (es) Anticuerpos anti-fgfr2iiib afucosilados.
CO2019003178A2 (es) Compuestos de dinucleótidos cíclicos
CO2018006662A2 (es) Agonistas del receptor de apelina y métodos de uso
CO2017012995A2 (es) Derivados análogos de heteroarilos/arilo actvos como reguladores nrf2 y composiciones farmacéuticas de los mismos
CL2018000953A1 (es) 2,4-dihidroxi-nicotinamidas como agonistas del receptor de apelina (apj)
CL2017003404A1 (es) Compuestos antibacterianos
TWD193951S (zh) 車頂桿
ECSP16061758A (es) Moduladores de tetrahidropiridopirazinas de gpr6
MX374828B (es) Composiciones y metodos para alterar la señalizacion del segundo mensajero.
NI201700060A (es) Agonistas parciales del receptor de insulina
MX2019011496A (es) Composiciones de niraparib.
MX2018011194A (es) 6-hidroxi-4-oxo-1,4-dihidropirimidin-5-carboxamidas como agonistas del receptor de apelina (apj).
MX2018007155A (es) Heteroarilhidroxipirimidinonas como agonistas del receptor de apelina (apj).
UY37410A (es) Antagonistas de trpv4
CL2019003213A1 (es) Compuestos plaguicidas bicíclicos.
MX2020007565A (es) Nuevos oxadiazoles.
MX2016010529A (es) Pirazinas moduladoras de receptor 6 acoplado a la proteina g (gpr6).
AR106981A1 (es) Una composición antimicrobiana
BR112019007256A2 (pt) composições cosméticas
CO2019006901A2 (es) Receptores de células t con apareamiento mejorado
BR112015022932A2 (pt) lentes de contato de silicone com tratamento de argila aplicado às mesmas
MX2018004427A (es) Composicion heterofasica.